Stocks to buy: 6 stocks to watch out for an upside potential of up to 77%
ET Online|
1/6
Top stocks to buy this week
Stock: PDS Research House: JM Financial Advice: Buy Stock Price: Rs 441 1-year Target Price: Rs 780 Potential Upside: 76.9% Comment: Maintain ‘buy’ as increased outsourcing by global retailers, manufacturing operations turnaround, newer revenue streams and expanding US market penetration will support strong top-line growth over three years.
Getty Images
2/6
Stocks to watch out for
Stock: Eureka Forbes Research House: ICICI Securities Advice: Buy Stock Price: Rs 440 1-year Target Price: Rs 600 Potential Upside: 36.4% Comment: Maintain ‘buy’ rating as portfolio premiumisation, cost rationalisation and operating leverage are expected to support EBITDA margins in the future. Also, a well-balanced distribution channel and focus on improving service business are key strongholds.
Getty Images
3/6
Top stock picks
Stock: Welspun Living Research House: Asian Markets Securities Advice: Buy Stock Price: Rs 143 1-year Target Price: Rs 185 Potential Upside: 29.4% Comment: Initiate with ‘buy’ due to likely improvement in margins and return ratios in the future. Recovery in home textiles business, flooring segment expansion and net debt-free target by 2026-27 are key positives.
Getty Images
4/6
Stock recommendations this week
Stock: Rossari Biotech Research House: Anand Rathi Advice: Buy Stock Price: Rs 756 1-year Target Price: Rs 950 Potential Upside: 25.7% Comment: Initiate with ‘buy’ due to expectations of a good performance, aided by capacity expansion, product launches and better margins. Also, acquisition synergies, strong capex, robust R&D and geographical diversification are key positives.
Getty Images
5/6
Stocks to buy this week
Stock: Sobha Research House: HDFC Securities Advice: Buy Stock Price: Rs 2,180 1-year Target Price: Rs 2,639 Potential Upside: 21.1% Comment: Rate ‘buy’ due to client loyalty, design differentiation in premium offerings and likely strong pre-sales growth. Valuation support, free cash-flow generation, likely deleveraging are near-term catalysts for further rerating.
Getty Images
6/6
Stocks to buy: Full list
Stock: Mankind Pharma Research House: Motilal Oswal Advice: Buy Stock Price: Rs 2,214 1-year Target Price: Rs 2,650 Potential Upside: 19.7% Comment: Initiate with ‘buy’ due to expanded product offerings in major therapies, capitalising on leverage, gradual increase in share of chronic therapies, improving MR productivity, and footprint expansion in tier-1 cities.